News

Q1 2017 Update: DBM Invests in Cytation 5 Anchored Automated System

Discovery BioMed prides itself on utilizing the latest technology platforms and offering services based on these advanced systems. In H1 2017 DBM invested in a BioTek Cytation 5 anchored automatic robotics system supported by BioTek’s BioSpa 8 and a BioTek plate washer. Together this system provides high-content automated fluorescence, luminescence, brightfield imaging and plate reading modalities. After an initial period of set-up and optimization, DBM is now utilizing this platform for both its CRO services and R&D arms. One service that has proven popular with our large biopharma clients, leverages DBM’s expertise in renal biology and is a demonstration of the types of assays we offer is DBM’s in vitro 3D cyst formation assay. This is assay is directed towards clients and researchers with a principle interest in human renal diseases that exhibit cystogenesis as part of their pathology. As with all research projects undertaken by DBM, we base the assay on human tissue platforms. This enables greater translatability of the results and a better likelihood of eventual clinical success. This assay in particular relies...

Read More

Q4 2016 Update – DBM Participates at BIO’s 2016 International Conference and BIO’s 2016 Investor Forum, Continues an Active Intern Program

In June 2016, DBM's Dr. Erik Schwiebert and Dr. John Streiff, with support from our long-time consultant, Dr. Douglas Hay, traveled to San Francisco to participate in the annual BIO International Meeting. There, DBM met with over 40 companies within and outside the BIO Partnering Forum. The NIH NIDDK also nominated and supported DBM at the convention with an Exhibit Kiosk in the NIH Innovation Zone. DBM was humbled and grateful for this opportunity. DBM was also an active partner in the BioAlabama exhibit. Additionally, DBM was nominated by the NIH NDDK to participate in the Annual 2016 Bio Investor forum. And, in October, DBM traveled to San Francisco, once again, to present the results from an in vivo study with lead compounds from its Metabolic R&D program. DBM’s presentation was well received and its presence made possible by an NIDDK administrative supplement to an active SBIR award for registration and travel funds. DBM's Dr. Schwiebert declared that "DBM continues to be honored and grateful for the deep support from the NIDDK in our partnering...

Read More

DiscoveryBioMed, Inc. Declares a Sharpened Focus on Renal Cell Biology and Physiology and on Renal Diseases

Through both natural evolution of our R&D programs and within our CRO services business, DiscoveryBioMed, Inc. (DBM, Inc.) has identified a sharpening focus in Renal or Kidney Cell Biology and Physiology and in Renal Diseases over the last year, in 2016, and going forward. We invite interested parties to view our newly redesigned website where this focus is declared and apparent. It is ironic that DBM’s founder, Dr. Erik Schwiebert, first worked on Renal Cell Physiology while a lab technician, first year Ph.D. student, and Ph.D. candidate while in Dr. Bruce Stanton’s laboratory at Dartmouth. “In my very first memories of culturing rodent and human cells, I was involved in establishing primary cultures and growing those cultures and immortal cell lines from the nephron of the kidney so as to study the regulation of epithelial sodium and chloride channels in collecting duct-derived cells,” Erik explained. “I am very familiar with establishing and growing kidney cells as well as studying them and characterizing them. It is therefore not surprising that DBM has also gravitated to that...

Read More

It is who we are – It is what we do

Since the 'light bulb idea moment' in 2006 and the pre-launch and launch periods in 2007, DiscoveryBioMed, Inc. (DBM, Inc.) has held the solid core principle of Humanized Drug Discovery, the use of intact, living human cells in culture as the biologically-relevant and disease-relevant cell platforms on which to perform meaningful small molecule discovery and critical hit-to-lead and lead compound profiling. This core principle holds for both our internal R&D programs and our contract research organization (CRO) services business. As the newest Geico commercials say: “It is who we are - it is what we do.” “If you are the biotechnology company, DiscoveryBioMed, Inc., you like Humanized Drug Discovery – it’s what you do.” And it’s who we are… The dual or hybrid business model of performing R&D for ourselves and performing CRO services for others can only be accomplished by a small outfit by using the same core principle, methods, reagents, etc. (i.e., the same infrastructure). However, as early as December 2008 at the SEBIO Investor Forum, we presented as a new company to...

Read More

DiscoveryBioMed, Inc. announces a new internship program for 2016

DiscoveryBioMed, Inc. (DBM, Inc.) is pleased to announce the initiation of a new internship program in conjunction with the University of Alabama at Birmingham (UAB) that will begin in January 2016. DBM’s Dr. Erik Schwiebert directs and teaches the first introductory class called “Idea to IPO” in a Technology Entrepreneurship Certificate program and a series of courses focused on entrepreneurship on behalf of the Collat School of Business at UAB. Moreover, DBM is a local industry partner for a new UAB Experiences program directed by Dr. Lisa Marshall Schwiebert, Ph.D. and Jami Armbrester, MS that is funded by Burroughs-Wellcome and for a Design and Commercialization program in UAB’s Biomedical Engineering division directed by Dr. Alan Eberhart, Ph.D. “I attended these classes when I was a faculty member at UAB when the idea was incubating for DiscoveryBioMed, Inc. Shortly after DBM was founded, I was alerted to the fact that these classes needed a new instructor so I volunteered and we had the class at Innovation Depot for the first years of re-starting them,” explained Dr....

Read More

DiscoveryBioMed, Inc. participates in BIO 2015

DiscoveryBioMed, Inc. (DBM, Inc.) participated in BIO 2015 in Philadelphia, PA. DBM applied for and was selected to give an oral presentation in a public forum on DBM’s Humanized Drug Discovery contract research organization (CRO) services offerings. DBM’s CEO and Chief Scientific Officer Dr. Erik Schwiebert gave the presentation on behalf of DBM. Erik was joined by DBM’s long-time consultant, Dr. Douglas Hay, during DBM’s one-on-one partnering meetings with interested Biotechnology and Biopharmaceutical parties on DBM’s R&D programs and its valuable lead therapeutic assets and on their interests in DBM’s services capabilities. “DBM had nearly 30 meetings in 2 intensive days at BIO, including additional meetings outside of the forum with major Biopharmaceutical firms,” explained Dr. Schwiebert. DBM is already planning to join BIO 2017 in San Francisco, CA because it has multiple clients and interested parties on the West Coast for its R&D programs and CRO services offerings. About DiscoveryBioMed, Inc. DBM focuses on Humanized Drug Discovery, the use of intact, living human cells derived from normal or diseased adult tissue as physiologically-relevant and...

Read More